Alpha-glucosidase inhibitors for type 2 diabetes mellitus

Laar, F.A. van de; Lucassen, Peter; Akkermans, Reinier; Lisdonk, E.H. van de; Rutten, Guy E.H.M.; Weel, Chris van

doi:10.1002/14651858.cd003639.pub2

Cited by 237 publications

(168 citation statements)

References 62 publications

Supporting

Mentioning

159

Contrasting

Unclassified

Order By: Relevance

“…Choosing specific diabetes interventions and their roles in treating type 2 diabetes Numerous reviews have focused on the characteristics of the specific diabetes interventions listed below [25][26][27][28][29][30][31][32][33][34]. In addition, meta-analyses and reviews have summarised and compared the glucose-lowering effectiveness and other characteristics of the medications [35][36][37].…”

Section: Non-glycaemic Effects Of Medicationsmentioning

confidence: 99%

“…They are less effective in lowering glycaemia than metformin or the sulfonylureas, reducing HbA 1c levels by 0.5-0.8 percentage points [29]. Since carbohydrate is absorbed more distally, malabsorption and weight loss do not occur; however, increased delivery of carbohydrate to the colon commonly results in increased gas production and gastrointestinal symptoms.…”

Section: Medicationsmentioning

confidence: 99%

“…Since carbohydrate is absorbed more distally, malabsorption and weight loss do not occur; however, increased delivery of carbohydrate to the colon commonly results in increased gas production and gastrointestinal symptoms. In clinical trials, 25-45% of participants have discontinued α-glucosidase inhibitor use as a result of this side effect [29,60].…”

Section: Medicationsmentioning

confidence: 99%

See 2 more Smart Citations

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy

et al. 2008

View full text Add to dashboard Cite

The consensus algorithm for the medical management of type 2 diabetes was published in August 2006 with the expectation that it would be updated, based on the availability of new interventions and new evidence to establish their clinical role. The authors continue to endorse the principles used to develop the algorithm and its major features. We are sensitive to the risks of changing the algorithm cavalierly or too frequently, without compelling new information. An update to the consensus algorithm published in January 2008 specifically addressed safety issues surrounding the thiazolidinediones. In this revision, we focus on the new classes of medications that now have more clinical data and experience.

show abstract

Section: Non-glycaemic Effects Of Medicationsmentioning

confidence: 99%

Section: Medicationsmentioning

confidence: 99%

Section: Medicationsmentioning

confidence: 99%

See 1 more Smart Citation

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy

et al. 2008

View full text Add to dashboard Cite

show abstract

“…The inhibition of alpha-glycosidase activity would therefore be an effective approach to control hyperglycemia (Matsui et al, 2007). Acarbose, Voglibose, and Migritol, specific pancreatic alpha-glycosidase inhibitors, are used clinically to prevent hyperglycemia (van de Laar et al, 2005). There has recently been an increased interest in natural and nutraceutical products for diabetes control.…”

Section: Discussionmentioning

confidence: 99%

Study on the Postprandial Glucose Responses to a Chlorogenic Acid-Rich Extract of Decaffeinated Green Coffee Beans in Rats and Healthy Human Subjects

Iwai

Narita

Fukunaga

et al. 2012

FSTR

View full text Add to dashboard Cite

The objective of this investigation was to assess the antihyperglycemic effects of an extract of decaffeinated green coffee beans (EDGCB). Despite the potential properties attributed to this compound, little is known about its action in vivo. In rats, EDGCB significantly decreased postprandial blood glucose levels when administered with each of the 4 carbohydrate types (sucrose, maltose, glucose, and soluble starch). An optimum effect was observed when EDGCB was administered at the beginning of the carbohydrate challenge. In the clinical trial, plasma glucose levels were significantly reduced by administering doses of 100 and 300 mg EDGCB after ingestion of 200 g carbohydrate, particularly in subjects with a high glycemic response. No significant differences were observed in plasma insulin profiles, however, over the course of the experiment.

show abstract

“…DPP-IV rapidly destroys the incretin hormones, glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). These peptides are members of the glucagon peptide superfamily that helps the body produce more insulin when it is needed [1,[7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

In VITRO ANTIDIABETIC EFFECTS OF FERULA ASSA-FOETIDA EXTRACTS THROUGH DIPEPTIDYL PEPTIDASE IV AND Α-Glucosidase INHIBITORY ACTIVITY

Adel

Kumle

Niazi‎

2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: Diabetes mellitus (DM) causes hyperglycemia, which is one of the most common diseases in the world. One of the strategies for the treatment of diabetes is maintaining postprandial glucose level through inhibition of dipeptidyl peptidase IV (DPP-IV) and α-glucosidase enzymes. The aim of this study was to determine in vitro antidiabetic potential of Ferula assa-foetida via DPP-IV and α-glucosidase inhibitory activities.Methods: F. assa-foetida seeds were extracted in methanol, ethanol, ethanol-methanol, and water. Inhibitory activity on DPP-IV and α-glucosidase was performed in vitro and measured spectrophotometrically at λ=405 nm. Results:The result showed that the F. assa-foetida seed extract is effective against both enzymes. All fractions had DPP-IV inhibitory activity, but the ethanolic fraction had the highest inhibitory activity on DPP-IV enzyme and significantly decreased DPP-IV activity (24.5%). With respect to α-glucosidase inhibitory activity, the aqueous extract has the highest inhibitory activity (28%). Conclusion:According to the results of this study, F. assa-foetida contains DPP-IV and α-glucosidase inhibitors and could be a potential source for the discovery of active constituents as α-glucosidase and DPP-IV inhibitors to treat Type 2 DM.

show abstract

Alpha-glucosidase inhibitors for type 2 diabetes mellitus

Cited by 237 publications

References 62 publications

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy

Study on the Postprandial Glucose Responses to a Chlorogenic Acid-Rich Extract of Decaffeinated Green Coffee Beans in Rats and Healthy Human Subjects

In VITRO ANTIDIABETIC EFFECTS OF FERULA ASSA-FOETIDA EXTRACTS THROUGH DIPEPTIDYL PEPTIDASE IV AND Α-Glucosidase INHIBITORY ACTIVITY

Contact Info

Product

Resources

About